Phase II Study of BIBF 1120 in Recurrent Glioblastoma Multiforme.
Phase of Trial: Phase II
Latest Information Update: 10 Nov 2012
At a glance
- Drugs Nintedanib (Primary)
- Indications Glioblastoma
- Focus Biomarker; Therapeutic Use
- 10 Jun 2017 Biomarkers information updated
- 04 Apr 2012 Status changed from active, no longer recruiting to discontinued, as reported at the 103rd Annual Meeting of the American Association for Cancer Research.
- 04 Apr 2012 Results presented at the 103rd Annual Meeting of the American Association for Cancer Research.